APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2034 November 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number: Pegylated Interferon alfa-2A		Fax Number:		
Initial application — chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant Applications from any specialist. Approvals valid for 18 months. Prerequisites(tick boxes where appropriate)				
Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection Patient has chronic hepatitis C and is co-infected with HIV Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant Maximum of 48 weeks therapy				
Renewal — Chronic hepatitis C - genotype 1 infection Current approval Number (if known):				

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2034 November 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Pegylated Interferon alfa-2A - continued				
Applications only from a gastroenterologist, infection Prerequisites (tick boxes where appropriate) Patient has chronic hepatitis C, get and Patient has had previous treatment and Patient has responder relaps or Patient was a partial responder.	t with pegylated interferon and ribavirin			
and Patient received interferon treatment prior to 2004 and Patient is to be treated in combination with boceprevir and Maximum of 48 weeks therapy				
Initial application — chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV Applications from any specialist. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)				
Patient has chronic hepatitis C, genotype 2 or 3 infection and Maximum of 6 months therapy				

I confirm the above details are correct and that in signing this form I understand I may be audited.

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 3 Form SA2034 November 2025

APPLICAI	NT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:		First Names:	First Names:		
Name:		Surname:	Surname:		
Address: .		DOB:	Address:		
		Address:			
Fax Numb	er:		Fax Number:		
Pegylate	ed Interferon alfa-2A - continued				
Application	plication — Hepatitis B ons only from a gastroenterologist, infection sites(tick boxes where appropriate)	ous disease specialist or general physician. Approva	ls valid for 18 months.		
		infection (HBsAg positive for more than 6 months)			
and	Patient is Hepatitis B treatment-na	ive			
and	d ALT > 2 times Upper Limit of Norm	nal			
and HBV DNA < 10 log10 IU/ml					
and					
	HBeAg positive or				
	Serum HBV DNA greater that fibrosis)	an or equal to 2,000 units/ml and significant fibrosis ((Metavir Stage F2 or greater or moderate		
and					
and					
and	No continuing alcohol abuse or intravenous drug use				
and	Not co-infected with HCV, HIV or HDV and				
and	Neither ALT nor AST > 10 times upper limit of normal				
	No history of hypersensitivity or contraindications to pegylated interferon				
and	and Maximum of 48 weeks therapy				
Initial application — myeloproliferative disorder or cutaneous T cell lymphoma Applications from any relevant practitioner. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)					
or	Patient has a cutaneous T cell lym	phoma*			
	Patient has a myeloprolifera	tive disorder*			
	Patient is intolerant of hydro	xyurea			
	and Treatment with anagrelide a	nd busulfan is not clinically appropriate			
or	or				
	Patient has a myeloprolifera	tive disorder			
	Patient is pregnant, planning	g pregnancy or lactating			

I confirm the above details are correct and that in signing this form I understand I may be audited.

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 4 Form SA2034 November 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Pegylated Interferon alfa-2A - continued		
Patient has a cutaneous T coor Patient has a cutaneous T coor Patient has a myelopi and Remains intolei	vals valid for 12 months. on e and patient is benefitting from treatment cell lymphoma*	d busulfan remains clinically inappropriate
Note: Indications marked with * are unapproved in	ndications.	
Initial application — post-allogenic bone marro Applications from any relevant practitioner. Appro Prerequisites(tick box where appropriate) Patient has received an allogeneic bone		pse
Renewal — post-allogenic bone marrow transp	plant	
Current approval Number (if known):		
Applications from any relevant practitioner. Appro Prerequisites (tick box where appropriate)	vals valid for 3 months.	
Patient is responding and ongoing treatr Note: Indications marked with * are unapproved in		